Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017

Abstract Objective: to investigate sociodemographic and clinical characteristics of users of atypical antipsychotics receiving care via the Specialized Component of Pharmaceutical Assistance (Componente Especializado da Assistência Farmacêutica - CEAF), for the treatment of schizophrenia in Brazil, between 2008 and 2017. Methods: this was a retrospective cohort study using records of the authorizations for high complexity procedures retrieved from the Outpatient Information System of the Brazilian National Health System, from all Brazilian states. Results: of the 759,654 users, 50.5% were female, from the Southeast region (60.2%), diagnosed with paranoid schizophrenia (77.6%); it could be seen a higher prevalence of the use of risperidone (63.3%) among children/adolescents; olanzapine (34.0%) in adults; and quetiapine (47.4%) in older adults; about 40% of children/adolescents were in off-label use of antipsychotics according to age; adherence to CEAF was high (82%), and abandonment within six months was 24%. Conclusion: the findings expand knowledge about the sociodemographic and clinical profile of users and highlight the practice of off-label use.

[1]  Tumaini R. Coker,et al.  Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. , 2022, JAMA.

[2]  A. L. Ribeiro,et al.  Estatística Cardiovascular – Brasil 2021 , 2022, Arquivos brasileiros de cardiologia.

[3]  L. Kubzansky,et al.  A sad heart: Depression and favorable cardiovascular health in Brazil. , 2020, Preventive medicine.

[4]  D. Malta,et al.  Saúde cardiovascular e validação do escore autorreferido no Brasil: uma análise da Pesquisa Nacional de Saúde , 2020, Ciência & Saúde Coletiva.

[5]  Giseli Nogueira Damacena,et al.  Pesquisa Nacional de Saúde 2019: histórico, métodos e perspectivas , 2020, Epidemiologia e Serviços de Saúde.

[6]  D. Malta,et al.  Cardiovascular Disease Mortality According to the Brazilian Information System on Mortality and the Global Burden of Disease Study Estimates in Brazil, 2000-2017. , 2020, Arquivos brasileiros de cardiologia.

[7]  M. Brauer,et al.  Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study , 2020, The Lancet.

[8]  David R. Williams,et al.  Cumulative Psychosocial Stress and Ideal Cardiovascular Health in Older Women: Data by Race/Ethnicity , 2019, Circulation.

[9]  S. Janković,et al.  Status of cardiovascular health in the Republic of Serbia: Results from the National Health Survey , 2019, PloS one.

[10]  M. Cushman,et al.  Ideal cardiovascular health, glycaemic status and incident type 2 diabetes mellitus: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study , 2019, Diabetologia.

[11]  D. Davidov,et al.  Length of Residence and Cardiovascular Health among Afro-Caribbean Immigrants in New York City , 2018, Journal of Racial and Ethnic Health Disparities.

[12]  F. Lobelo,et al.  Ideal Cardiovascular Health and Incident Cardiovascular Disease Among Adults: A Systematic Review and Meta‐analysis , 2018, Mayo Clinic proceedings.

[13]  P. Wilson,et al.  Prevalence of Ideal Cardiovascular Health Metrics in the Million Veteran Program. , 2018, The American journal of cardiology.

[14]  L. Gutierrez,et al.  Ideal Cardiovascular Health in the southern cone of Latin America. , 2018, Public health.

[15]  I. Benseñor,et al.  Ideal cardiovascular health score at the ELSA-Brasil baseline and its association with sociodemographic characteristics. , 2017, International journal of cardiology.

[16]  E. Odom,et al.  Cardiovascular Health Status by Occupational Group - 21 States, 2013. , 2016, MMWR. Morbidity and mortality weekly report.

[17]  W. Maziak,et al.  A Systematic Review of the Prevalence and Outcomes of Ideal Cardiovascular Health in US and Non-US Populations. , 2016, Mayo Clinic proceedings.

[18]  S. Frisbee,et al.  Changes in Cardiovascular Health in the United States, 2003–2011 , 2015, Journal of the American Heart Association.

[19]  P. Dubbert,et al.  Prevalence and changes over time of ideal cardiovascular health metrics among African-Americans: the Jackson Heart Study. , 2015, Preventive medicine.

[20]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[21]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[22]  B. Duncan,et al.  Evolution of diabetes in Brazil: prevalence data from the 2013 and 2019 Brazilian National Health Survey. , 2022, Cadernos de saude publica.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .